FDA considers relaxing electroshock device regulation

The FDA is weighing whether to downgrade the risk classification of electroshock devices used to treat major depression and other diseases, thus allowing devicemakers to introduce new products without costly clinical tests. Advocates say the treatment is much safer than it's been in the past, while opponents worry that the procedure causes memory loss and brain damage. An FDA advisory panel will review the proposal this week, according to the New York TimesReport

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.